PR Newswire
PALO ALTO, Calif. , June 3, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases, today announced that David Cory , President and CEO, will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, June 8, 2022 at 9:00 AM ET in New York City . The Company will also host one-on-one meetings with investors at the conference.
A live webcast of the presentation will be available on the Investors section of the Eiger BioPharmaceuticals website at www.eigerbio.com . A replay of the presentation will be available on the website for at least 90 days.
About EigerEiger?is a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases. The Eiger HDV platform includes two first-in-class therapies in Phase 3 that target critical host processes involved in viral replication. Eiger is also developing peginterferon lambda as a therapeutic for COVID-19 and reported positive results from TOGETHER, a Phase 3 investigator-initiated study.
All five?Eiger?rare disease programs have been granted FDA Breakthrough Therapy designation: lonafarnib and peginterferon lambda for HDV, Zokinvy for progeria, and avexitide for both congenital hyperinsulinism and post-bariatric hypoglycemia.
For additional information about?Eiger?and its clinical programs, please visit?www.eigerbio.com.
Contacts
Investors:
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com
Media:
Sarah Mathieson
SVP, Corporate Affairs
smathieson@eigerbio.com
SOURCE Eiger BioPharmaceuticals, Inc.